LanzaTech Global Inc.LNZA
▲ PositiveCapitalrelevance
Q2 loss narrowed sharply and guidance reinstated, signaling improved financial trajectory.
Impact on stocks 1
Synthetic Biology (non-pharma)
LanzaTech Global Inc.LanzaTech Global reported second-quarter 2026 revenue that was broadly flat from a year earlier, while sharply lower operating expenses helped narrow its adjusted EBITDA loss as the company continues shifting from an R&D-led model toward project development and commercialization. The company reported second-quarter revenue of $9 million, compared with $9.1 million in the same quarter of 2025. Operating expenses declined 67% to $11.7 million from $35.1 million, while adjusted EBITDA loss narrowed to $7.6 million from a loss of $29.7 million a year earlier. LanzaTech is advancing ISCC EU certification for its China-produced ethanol, which could open European and U.K. regulated fuel markets and support stronger demand and pricing as early as the fourth quarter. The company ended June with $45 million in cash and reinstated 2026 guidance for $50 million to $55 million of revenue, a $22 million to $26 million adjusted EBITDA loss and $51 million to $55 million of operating expenses.
LanzaTech Global Inc.Q2 loss narrowed sharply and guidance reinstated, signaling improved financial trajectory.